Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.

Core Insights - The emergence and rapid rise of GLP-1 obesity drugs is a significant development in the pharmaceutical industry, with Novo Nordisk leading the way after receiving FDA approval for Wegovy in mid-2021 [1] Company Overview - Novo Nordisk's stock has declined from its peak last year but remains significantly higher than pre-approval levels [2] - The company faces competition from Eli Lilly, which has introduced Zepbound, a competitor in the GLP-1 obesity drug market [2][3] Market Dynamics - The demand for weight loss drugs is expected to surge, with analysts predicting the global market for these medications to grow from an estimated $12.8 billion this year to nearly $105 billion by 2035 [4] - This represents an eight-fold increase in the market size within a few years, benefiting all manufacturers of such drugs [5] - As a first mover in the market, Novo Nordisk is positioned to capitalize on the anticipated growth in demand for obesity treatments [5]